Comparison of angiotensin II receptor antagonists

European Journal of Clinical Investigation

Volumn 31, Issue 8, 2001, Pages 698-706

  Kirch, W ^a   Horn, B ^a   Schweizer, J ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Angiotensin II receptor antagonists; Hypertension

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; KENZEN; LISINOPRIL; LORTAAN; LOSAPREX; LOSARTAN; LOSARTAN POTASSIUM; NEO LOTAN; NIFEDIPINE; NU LOTAN; PERINDOPRIL; TELMISARTAN; TOLBUTAMIDE; VALSARTAN; WARFARIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GERIATRIC PATIENT; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034869208     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00871.x     Document Type: Review

References (58)

1. Valsartan preclinical and clinical profile of an antihypertensive angiotensin II antagonist
2. Angiotensin II receptor antagonists
3. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
4. A phase I clinical study of BIBR277 capsules in healthy normal subjects
5. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an angiotensin II antagonist) in subjects with hypertension
6. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
7. 14C-candesartan cilexetil in healthy volunteers
8. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
9. Angiotensin receptor antagonists focus on losartan
10. Angiotensin II receptors and angiotensin II receptor antagonists
11. The pharmacokinetics of losartan in renal insufficiency
12. Influence of telmisartan, a non-peptide angiotensin II receptor antagonist, on steady state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects
13. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function
14. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged
15. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function
16. Effects of candesartan on the proteinuria of chronic glomerulonephritis
17. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression
18. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes
19. 1 antagonists assessed by Schild regression technique in man
20. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
21. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
22. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects
23. Pilot study of the uricosuric effect of Dup-753, a new angiotensin II receptor antagonist in healthy subjects
24. A randomized, placebo-controlled, double-blind parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
25. The efficiency and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
26. 1-rezeptorantagonisten
27. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
28. 1 receptor antagonist irbesartan in hypertension
29. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect
30. Single dose study of pharmacodynamics and pharmacokinetics of the angiotensin II antagonist BIBR0227SE
31. Telmisartan
32. 1-rezeptorantagonisten
33. A comparison of cough in hypertensive patients receiving telmisartan, lisinopril, or placebo
34. Twenty-four-hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension
35. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension
36. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension
37. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
38. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring
39. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
40. Comparison of the effects of candesartan and losartan on ambulatory blood pressure in patients with essential ambulatory hypertension. A forced titration study
41. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension
42. A comparison of the blood pressure profile of telmisartan and losartan at 18-24 hours post-dosing as measured by ambulatory blood pressure monitoring
43. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotension II dose-response and radioligand receptor assay
44. Candesartan cilexetil has the highest pharmacologic potency of various AT1 antagonists - Assessed by the Schild regression technique in man
45. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
46. ELITE II (Evaluation of Losartan in the Elderly) Study - The Losartan Heart Failure Survival Study. Plenary Session XII. Late-Breaking Clinical Trials
47. Disappointing results for losartan in ELITE-2
48. Effects of losartan on hypertension and left ventricular mass: A long-term study
49. Regression of left ventricular hypertrophy following angiotensin II receptor blockade: Valsartan in left ventricular hypertrophy
50. Candesartan cilexetil. A review of its use in essential hypertension
51. Cough and angiotensin II receptor antagonists: Cause or confounding?
52. A comparison of cough in hypertensive patients receiving telmisartan, enalapril, or hydrochlorothiazide
53. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension
54. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population
55. The ELITE Study. What are the implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly study